Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.

Details

Serval ID
serval:BIB_98ACC5BD24F7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
Journal
Cancer chemotherapy and pharmacology
Author(s)
Dao K., Lu Y., Peer C.J., Figg W.D., Stadelmann R., Burnier M., Buclin T., Kissling S.
ISSN
1432-0843 (Electronic)
ISSN-L
0344-5704
Publication state
Published
Issued date
01/2017
Peer-reviewed
Oui
Volume
79
Number
1
Pages
215-218
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
High cut-off dialysis, increasingly used in multiple myeloma patients, is susceptible to influence anticancer drug elimination. We report about lenalidomide disposition in a patient on high cut-off dialysis for renal failure secondary to myeloma cast nephropathy.
The patient received a higher dosage of lenalidomide (5 mg b.i.d.), owing to concerns about a potential decrease in lenalidomide exposure during dialysis sessions. A set of blood samples was taken in order to develop a pharmacokinetic model accounting for lenalidomide concentrations in this setting.
According to our model, the area under the curve was 3273 µg h/L, i.e., 60% higher than expected under usual dosage (25 mg q.d.) with normal renal function. Despite this, the patient did not develop major hematological toxicity.
Lenalidomide doses of 5 mg b.i.d. led to high exposure in a patient with renal failure undergoing high cut-off dialysis. Yet, the dosage of 5 mg q.d. recommended in conventional dialysis would probably be adequate in such patients.

Pubmed
Web of science
Create date
29/12/2016 10:36
Last modification date
17/09/2020 9:18
Usage data